Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Macular Edema Eye Diseases Macular Degeneration Macular Edema Retinal Degeneration Retinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

East Bay Retina Consultants, Inc., Oakland, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

macular edema due to diabetic retinopathy

Exclusion criteria

vision loss from other ocular disease
intraocular surgery within 3 months
intraocular anti-VEGF or steroids within 3 months
HbA1c >12

Treatment and study plan

mecamylamine

Drug

topical ocular drops

Sponsors and collaborators

Lead sponsor

CoMentis

Industry

Collaborators

Juvenile Diabetes Research Foundation

Registry information

Official study title

Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)

Important dates

Study start: 2007
Study completion: 2008
First posted: Sep 28, 2007
Registry last updated: Apr 8, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed